

A2 Sub B2
3. (amended) The method of claim 1 wherein the matrix is in a form selected from the group consisting of gels[,] or foams, suspensions, microcapsules, solid polymeric supports, or fibrous structures.

A3 Sub B3
6. (amended) The method of claim 5 wherein the matrix is formed of a material selected from the group consisting of polyhydroxy acids, polyorthoesters, polyanhydrides, proteins, carbohydrates[,] or polysaccharides, polyphosphazenes, polyalkylene oxides and combinations thereof.

A4 Sub B4
8. (amended) The method of claim 1 wherein the matrix further comprises biologically active compounds selected from the group consisting of [anti-inflammatory agents], prostaglandins, prostanoids, [angiotensin and related compounds] compounds regulating the renin-angiotensin axis, tyrosine kinase inhibitors, immunosuppressants, [vitamins,] glucocorticoids, anti-oxidants, free radical scavengers, peptide hormones, angiogenic and angiogenic inhibitory factors, and combinations thereof.

AS Sub B5
11. (amended) A composition for inhibiting [intimal smooth muscle cell proliferation or] mechanisms involved in restenosis of a blood vessel following injury to vascular tissue of the blood vessel in a patient in need of treatment thereof, comprising a biocompatible matrix shaped for implantation adjacent to a blood vessel, the matrix having seeded therein or thereon dissociated endothelial cells, wherein the endothelial cells are in an amount effective to inhibit smooth muscle cell proliferation at the site of the injury.

U.S. SERIAL NO.: 08/458,978
FILED: June 2, 1995
AMENDMENT

Sub B⁶
13. (amended) The composition of claim 11 wherein the matrix is in a form selected from the group consisting of gels[,] or foams, suspensions, microcapsules, solid polymeric supports, or fibrous structures.

Sub B⁸
16. (amended) The composition of claim 15 wherein the matrix is formed of a material selected from the group consisting of polyhydroxy acids, polyorthoesters, polyanhydrides, proteins, carbohydrates[,] or polysaccharides, polyphosphazenes, and combinations thereof.

Sub B⁹
18. (amended) The composition of claim 11 wherein the matrix further comprises biologically active compounds selected from the group consisting of [anti-inflammatory agents,] prostaglandins, prostanoids, [angiotensin and related compounds] compounds regulating the renin-angiotensin axis, tyrosine kinase inhibitors, immunosuppressants, [vitamins,] glucocorticoids, anti-oxidants, free radical scavengers; peptide hormones, angiogenic and angiogenic inhibitory factors.

Please cancel claim 19.

Remarks

Rejections under 35 U.S.C. §112, second paragraph

Claims 1-19 were rejected under 35 U.S.C. §112, second paragraph, as indefinite. These rejections are respectfully traversed if applied to the amended claims.